In a significant advancement for hemophilia care, the FDA has approved two novel treatments: Qfitlia, a first-in-class RNAi therapeutic, and Fitusiran, both designed for patients with Hemophilia A and B. Sanofi’s Qfitlia has received recognition as the first therapy to effectively address hemophilia with or without inhibitors. The approval of Fitusiran is particularly noteworthy as it offers prophylactic treatment options, potentially reducing bleed episodes in patients aged 12 and up. Additionally, a companion diagnostic, an antithrombin blood test from Siemens Healthineers, has also been cleared to support the use of Qfitlia. This development marks a substantial enhancement to the hemophilia treatment landscape, promising better management and improved patient outcomes.